Fig. 4: Interleukin-3 is produced by T cells in COVID-19.
From: Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections
a Absolute numbers of circulating T cells in SARS-CoV-2+ patients from their admission to ICU and 1 to 7 days later. p = 0.0154 (d6). n = 9. b Correlation between the absolute numbers of circulating T cells and circulating pDCs in SARS-CoV-2+ patients. Pearson r test (p < 0.0001). n = 87. c Absolute numbers of circulating CD4+ T cells, CD8+ T cells, and B cells expressing IL-3 in SARS-CoV-2+ patients. p = 0.024 for CD4 T cells vs CD8 T cells; p = 0.0036 for CD4 T cells vs B cells. n = 7. d Correlation between the number of circulating T cells and the number of circulating pDCs of patients with pulmonary diseases. Pearson r test (p < 0.0001). n = 12. e Correlation between the percentage of BALF T cells and the percentage of BALF pDCs of patients with pulmonary diseases. Pearson r test (p = 0.0288). n = 20. f Percentage of T cells in the BALF of patients with pulmonary diseases with high or low IL-3 BALF levels. p = 0.0452. n = 13. Data are mean ± S.E.M., *P < 0.05, **P < 0.01, ***P < 0.001, unpaired, two-tailed Student’s t test using Welch’s correction for unequal variances and paired, two-tailed Student’s t test were used. Source data are provided as a Source Data file.
